Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EFFECT OF CHRONIC ANTIPSYCHOTIC DRUG-TREATMENT ON PREPROSOMATOSTATIN AND PREPROTACHYKININ-A MESSENGER-RNA LEVELS IN THE MEDIAL PREFRONTAL CORTEX, THE NUCLEUS-ACCUMBENS AND THE CAUDATE-PUTAMEN OF THE RAT
Autore:
MARCUS MM; NOMIKOS GG; MALMERFELT A; ZACHRISSON O; LINDEFORS N; SVENSSON TH;
Indirizzi:
KAROLINSKA INST,DEPT PHYSIOL & PHARMACOL,DIV PHARMACOL S-17177 STOCKHOLM SWEDEN KAROLINSKA INST,DEPT PHYSIOL & PHARMACOL,DIV PHARMACOL S-17177 STOCKHOLM SWEDEN KAROLINSKA INST,KAROLINSKA HOSP,DEPT CLIN NEUROSCI,PSYCHIAT SECT S-17177 STOCKHOLM SWEDEN
Titolo Testata:
Molecular brain research
fascicolo: 2, volume: 45, anno: 1997,
pagine: 275 - 282
SICI:
0169-328X(1997)45:2<275:EOCADO>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
D2-DOPAMINE RECEPTOR OCCUPANCY; MESSENGER-RNA EXPRESSION; CLOZAPINE-TREATED PATIENTS; SUBSTANCE-P; DOPAMINE D-2; TACHYKININ BIOSYNTHESIS; NEUROLEPTIC TREATMENT; SEROTONIN REGULATION; NEUROKININ-A; BRAIN;
Keywords:
HALOPERIDOL; CLOZAPINE; AMPEROZIDE; RACLOPRIDE; ANTIDEPRESSANT DRUG; SEROTONIN; SUBSTANCE P; SOMATOSTATIN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
59
Recensione:
Indirizzi per estratti:
Citazione:
M.M. Marcus et al., "EFFECT OF CHRONIC ANTIPSYCHOTIC DRUG-TREATMENT ON PREPROSOMATOSTATIN AND PREPROTACHYKININ-A MESSENGER-RNA LEVELS IN THE MEDIAL PREFRONTAL CORTEX, THE NUCLEUS-ACCUMBENS AND THE CAUDATE-PUTAMEN OF THE RAT", Molecular brain research, 45(2), 1997, pp. 275-282

Abstract

In situ hybridization histochemistry was used to study the expressionof preprosomatostatin (PPSOM) and preprotachykinin A (PPT-A) mRNA in the medial prefrontal cortex (mPFC), the nucleus accumbens (NAC) and the caudate putamen (CP) of the rat after chronic (21 days) treatment with the classical antipsychotic drug haloperidol (1 mg/kg i.p.), the atypical antipsychotic drugs clozapine (15 mg/kg i.p.) and amperozide (5 mg/kg i.p.), and the selective dopamine (DA)-D-2/D-3 receptor antagonist raclopride (2 mg/kg i.p.). Whereas amperozide markedly elevated the numerical density of PPSOM mRNA expressing neurons in the mPFC (52%), the other drugs did not significantly affect PPSOM mRNA levels in any of the brain regions studied. Amperozide also altered PPT-A mRNA expression in the mPFC, i.e. a decrease (22%) was found. Of the other drugs tested only haloperidol significantly decreased PPT-A mRNA levels in the NAC shell (14%), in the dorso-lateral CP (19%) and in the medial CP (15%). In view of the differences between amperozide and the other drugs studied, as regards both pre-clinical and clinical characteristics, we suggest that the specific effects of amperozide on PPSOM and PPT-A mRNA in the mPFC may be related to its 5-HT releasing action in the frontal cortex, an effect possibly caused by its alpha(2)-adrenoceptor blocking activity. This effect, in turn, may be related to an antidepressant-like action that this compound exhibits in animal studies. The decrease in PPT-A mRNA levels seen after the haloperidol treatment is probably due to its potent DA-D-2 receptor antagonism and may be related to side-effects, rather than therapeutic effects of this drug.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/06/20 alle ore 09:42:38